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in the symptomatic treatment




Neuroendocrine tumours (NETs) are a heterogeneous group of tumours originating from endocrine cells
scattered throughout the body and which form the diffuse endocrine system. Functioning tumours produce
hormones or catecholamines which are responsible for the characteristic clinical picture.
Surgery is the treatment of choice for patients with NETs, although it can rarely be radical. Somatostatin
analogues play an important role in the drug treatment of NETs, as they effectively control the signs and
symptoms of the excessive release of hormones by these tumours. Treatment with somatostatin analogues
improves the quality of life for the patient and prolongs survival.
We report on four patients with neuroendocrine tumours managed with somatostatin analogues: one male
patient with carcinoid syndrome; one female patient with clinical manifestations of functioning VIPoma; and
two male patients with ectopic ACTH syndrome.
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Introduction
Neuroendocrine tumours (NETs) are a hetero-
geneous group of tumours originating from the
endocrine cells scattered throughout the human
body and which form the diffuse endocrine system
[1]. These tumours are rare and in most cases slow-
growing, small and malignant. They may be hor-
monally active (functioning tumours) or not (non-
functioning tumours). Functioning tumours pro-
duce hormones or catecholamines responsible for
the characteristic clinical picture. Carcinoids account
for the majority of NETs (approximately 50%) [1,
2]. The detectability of NETs is growing due to the
increasing availability of modern diagnostic meth-
ods [1, 3].
Surgery is the treatment of choice for patients
with NETs, including those with liver metastases.
However, in the majority of cases, because of ad-
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vanced disease, a complete resection of the tumour
is not possible [4, 5]. In patients who are not eligi-
ble for surgery, treatment is focused on improving
the quality of life. Such treatment includes soma-
tostatin analogues as first-line drugs and in some
cases interferon-a, radionuclide therapy or chemo-
therapy [4, 6].
Somatostatin analogues, especially those with
long-acting formulations, play a fundamental role
in the pharmacological treatment of NETs [4, 7].
Somatostatin analogues are considered the “gold
standard” in patients with neuroendocrine tumours
and manifestations of hormonal hypersecretion [8].
Aim
The aim of the paper is to present the outcomes
of octreotide treatment in four patients: one male
patient with carcinoid syndrome; one female pa-
tient with the clinical manifestations of a tumour
secreting vasoactive intestinal peptide (VIPoma); and
two male patients with ectopic ACTH syndrome.
They were hospitalized in the Department of Endo-
crinology and Diabetology, Medical College, Nico-
laus Copernicus University, Bydgoszcz, Poland, bet-
ween 2001 and 2006.
Case 1 — a patient with carcinoid
syndrome
In 1997 a 43-year-old male patient (TG) devel-
oped the first manifestations of carcinoid syndrome:
flushing and diarrhoea. A CT scan revealed two le-
sions in the liver suggestive of metastatic foci and
holography demonstrated a tumour in the caecum.
The diagnosis of carcinoid syndrome was confirmed
by the 24-hour urinary 5-hydroxyindoleacetic acid
(5-HIAA) value of 775.4 mmol/g of creatinine (nor-
mal values £ 23 mmol/g of creatinine). A right hemi-
colectomy was performed and a histopathological
examination of the resected material revealed a car-
cinoid tumour. After the surgery the patient was
managed with a prolonged-release somatostatin
analogue (lanreotide PR at the dose of 30 mg IM
q4w), which reduced the number of flushing epi-
sodes and loose stools. No new liver laesions were
revealed in imaging studies (CT, somatostatin re-
ceptor scintigraphy using OctreoScan). In Septem-
ber 1999 the patient discontinued treatment at the
Endocrinology Clinic and stopped receiving any so-
matostatin analogue. In May 2001 the patient pre-
sented to the Outpatient Clinic of the Endocrinolo-
gy Department of the University Hospital of the
Medical College, Nicolaus Copernicus University,
Bydgoszcz, Poland, with considerably exacerbated
symptoms of carcinoid syndrome (flushing, diar-
rhoea, weight loss and asthaenia).
It was decided to make an attempt at resecting
the metastatic foci of the carcinoid tumour visual-
ized in the somatostatin receptor scintigraphy us-
ing OctreoScan as two foci in the right lobe of the
liver. During the laparotomy, however, numerous
carcinoid metastases were discovered and the deci-
sion to close the patient was made. At that time the
patient was also diagnosed with chronic renal fail-
ure most likely caused by retroperitoneal fibrosis
and tricuspid insufficiency with right-sided heart
failure. In August 2001 the patient was started on
octreotide 0.1 mg SC tid for 2 weeks, followed by
a long-acting release (LAR) formulation at the dose
of 10 mg IM q4w for one year. During the treat-
ment we observed considerable improvement in his
well-being and exercise tolerance, the number of
flushing episodes decreased from 10 15 to 2 per
day and the number of stools from 8 to 3 per day.
The 24-hour urinary 5-HIAA excretion also decreased
from 130 mg/day in August 2001 to 80 mg/day in
March 2002. Between August 2002 and February
2003 the patient was not receiving the drug be-
cause the National Health Fund refused to reim-
burse the cost of it.  As octreotide could not be
continued, the use of 131I metaiodobenzylguanidine
(131I-MIBG) was considered. However, due to the
risk of the exacerbation of renal failure the patient
was not found eligible for radionuclide therapy. In
February 2003 the patient was started on LAR oct-
reotide at the dose of 20 mg q1m, followed by 30
mg q1m during hospitalization at our Department
of Endocrinology and Diabetology. While the treat-
ment improved the patient's well-being, signs and
symptoms of carcinoid syndrome and urinary 5-HIAA
excretion, we observed progressive cachexia, dete-
rioration in renal function and exacerbation of heart
failure symptoms. The patient passed away in Au-
gust 2004.
Case 2 — a patient with clinical
manifestations of VIPoma
In 2000 a 28-year-old female (JM) developed ab-
dominal pain and diarrhoea. The patient was pass-
ing up to 30 watery stools a day and had hypokali-
aemia. In order to establish the cause of these symp-
toms, investigations for infectious diseases, food al-
lergies, Crohn's disease and ulcerative colitis were
performed. An upper GI endoscopy revealed multi-
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ple oesophageal ulcerations, which healed following
several months of proton pump inhibitor treatment.
Abdominal ultrasound, upper and lower GI series
and a flexible sigmoidoscopy showed no abnormali-
ties. The diarrhoea persisted for two years and led to
emaciation in the patient. In 2002, endoscopic ultra-
sound revealed an 8 mm lesion in the head of the
pancreas. The somatostatin receptor scintigraphy
using 11In-OctreoScan revealed no signs of patholog-
ical focal tracer accumulation in the abdominal cavi-
ty. Gastrin levels were normal. The patient was start-
ed on short-acting octreotide, which resulted in clin-
ical improvement and resolution of the symptoms.
Treatment was continued with a LAR formulation at
the dose of 20 mg IM q29d. In May 2003 the patient
underwent a fine-needle aspiration biopsy of the hy-
poechoic lesion in the head of the pancreas detected
sonographically. The aspirate contained non-charac-
teristic proteinaceous content. Abdominal spiral CT
and endoscopic retrograde cholangiopancreatogra-
phy (ERCP) did not confirm the presence of the pan-
creatic tumour and no abnormalities were revealed
by colonoscopy or by mesenteric and coeliac arteri-
ography. The 24-hour urinary 5-HIAA excretion was
normal. The positron emission tomography (PET) scan
performed in October 2003 revealed no pathologies.
Chromogranin A levels determined during octreotide
treatment were in the range of the upper limit of
normality (19.4 U/l).
In 2004 the frequency of LAR octreotide dosing
was increased to 20 mg twice a month, as the symp-
toms had been worsening, achieving a consider-
able improvement of the patient's condition.
The somatostatin receptor scintigraphy using
99Tc-HYNIC-Tyr3-octreotide (99Tc-HYNIC-TOC) per-
formed in 2005 revealed pathological uptake of the
tracer in the head of the pancreas. CT and MRI scans
of the abdominal cavity and coeliac arteriography
did not confirm the presence of any focal lesion in
the pancreas. In spite of this, the patient was qual-
ified for surgical tumour resection in July 2006.
During surgery the patient underwent scintigra-
phy, endoscopy of the stomach and duodenum and
an ultrasound scan, all of which revealed no pathol-
ogies within the abdominal cavity. Lymph nodes
surrounding the common hepatic artery were col-
lected for intraoperative histopathology, which
showed no malignant infiltration. In view of the
above a decision not to proceed with the resection
of the head of the pancreas was made.
The patient continues to be treated with LAR
octreotide 20 mg q14d and passes approximately 3
formed stools a day. Periodically, she experiences
exacerbations of diarrhoea and hypokaliaemia which
require intravenous potassium supplementation. The
patient's condition is good and the periodic exacer-
bations do not interfere with her daily activities; the
patient remains in active employment.
Case 3 — a patient with ectopic ACTH
syndrome in the course of thymic
carcinoma
In 1995 a 31-year-old male (JB) developed grad-
ually increasing asthenia, atrophy of the limb mus-
cles, round face, striae, back pain and hypokaliaemia.
In 1996, based on a clinical picture of high serum
cortisol and abolition of the circadian variation in
cortisol levels (627 ng/ml at 8:00 am and 625 ng/ml
at midnight), a diagnosis of Cushing’s syndrome
was made. Very high ACTH levels (888 pg/ml at
8:00 am and 756 pg/ml at 10:00 pm), no patholo-
gies in the imaging studies of the adrenals and the
pituitary and the presence of a tumour in the supe-
rior mediastinum on a CT scan raised a suspicion of
ectopic ACTH syndrome. Following preparation with
aminoglutethimide, an inhibitor of adrenal steroido-
genesis, the patient underwent surgical resection
of the mediastinal tumour. Histopathological exa-
mination revealed thymic carcinoma with lymph
node involvement. Immunohistochemistry con-
firmed the tumour to be a functioning one (positive
NET markers: neuron-specific enolase and chromog-
ranin A). After the surgery the patient underwent
radio- and chemotherapy. The signs and symptoms
of Cushing’s syndrome resolved.
From 2003 onwards a gradually worsening as-
thenia and round facies were again observed. The
imaging studies (CT) performed at the beginning of
2005 revealed a mediastinal tumour, which was
subsequently resected (histopathology showed re-
current thymic carcinoma) and the patient under-
went chemotherapy. The clinical manifestations of
Cushing’s syndrome subsided for several months.
At the end of 2005, somatostatin receptor scintig-
raphy using OctreoScan revealed pathological trac-
er accumulation in the vicinity of the spine in the
mediastinum on the right. A CT scan did not reveal
a tumour but, in light of the persistent manifesta-
tions of Cushing’s syndrome, a repeat thoracotomy
was performed in March 2006 and the mediastinal
adipose tissue was removed. Due to persistently
elevated post-op cortisol levels, the patient was
started on LAR octreotide at the dose of 20 mg IM
q1m. The patient's well-being improved slightly but
the hypokaliaemia and weakness persisted. In May
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2006 the patient was diagnosed with diabetes mel-
litus and started on insulin.
In August 2006 the patient presented to the
Department of Endocrinology and Diabetology,
Medical College, Nicolaus Copernicus University,
Bydgoszcz, Poland, with considerable weakness and
severe hypokaliaemia (2.1 mmol/l). His serum corti-
sol levels were very high (111 mg/dl at 8:00 am [nor-
mal range: 4 38 mg/dl]). The patient was started on
aminoglutethimide and his octreotide dose was in-
creased to 30 mg q1m. During the hospitalization
the patient developed clinical and biochemical man-
ifestations of adrenal failure and the adrenal ste-
roidogenesis inhibitor was discontinued. The pa-
tient required temporary hydrocortisone treatment.
The subsequent injections of LAR octreotide at the
dose of 30 mg were given in September and Octo-
ber 2006. During the last two months of treatment
with the higher dose of octreotide the patient's well-
being improved considerably. The levels of cortisol
and potassium determined in October were normal
(10.0 mg/dl and 4.7 mmol/l respectively), as were as
his glucose levels (so that the patient no longer
required insulin). The patient remains in active em-
ployment.
Case 4 — a patient with ectopic ACTH
syndrome and a neuroendocrine
tumour of unknown location
In November 2006 a 26-year-old male (DB) de-
veloped rapidly worsening manifestations of Cush-
ing’s syndrome (characteristic distribution of the
adipose tissue, asthenia, hypertension, diabetes
mellitus, and purple-blue striae). In December 2003,
during hospitalization at the Department of Endo-
crinology and Diabetology, Medical College, Nico-
laus Copernicus University, Bydgoszcz, Poland, the
patient had been found to have elevated cortisol
levels (40.7 mg/dl at 8:00 am, 29.4 mg/dl at 8:00
pm) and very high ACTH levels (924 pg/ml at 8:00
am and 618 pg/ml at 8:00 pm). The dexametha-
sone suppression test showed the pituitary aetiolo-
gy of Cushing’s syndrome. No pituitary microade-
noma was demonstrated on MRI, but 99mTc-MIBI
scintigraphy revealed pathological tracer accumu-
lation in the pituitary gland. Following preparation
with mitotane (an inhibitor of adrenal steroidogen-
esis) the patient underwent transsphenoidal partial
resection of the pituitary gland. Histopathology did
not confirm the presence of adenoma. Despite the
surgery the levels of cortisol and ACTH continued to
be persistently high (ACTH: 162 pg/ml at 8:00 am
and 144 pg/ml at 8:00 pm). The patient was also
found to have elevated serum levels of chromogra-
nin A (22 U/l). Repeated dexamethasone suppres-
sion test indicated an adrenal or ectopic cause of
the hypercortisolaemia. No abnormalities were
found in the diagnostic investigations aimed at es-
tablishing the cause of the hypercortisolaemia (ab-
dominal CT and MRI scans, chest X-ray, thyroid gland
ultrasound, gastroscopy and colonoscopy). The chest
CT scan showed a focus measuring 11 ¥ 6 mm in
segment 4 of the right lung. After a pulmonologist
consultation a PET scan was performed, which
showed no increased metabolism in the location of
the lesion found on the CT scan. However, in the
anterior direction from the spine, a thickening of
tissues and increased glucose metabolism were ob-
served at the level of the first cervical vertebra. The
MRI scan did not visualize the focus described in
the PET scan. In May 2005, total body scintigraphy
with 131I-MIBG revealed, in the region of the left
phrenic dome and the left ventricle of the heart,
an area of radiotracer accumulation, and echocar-
diography revealed a hypoechoic area measuring
26 ¥ 8 mm near the lateral wall of the left ventricle.
These lesions were not, however, confirmed in the
MRI scan of the mediastinum. Due to the progres-
sive asthenia, the deterioration of the patient's con-
dition and the persistent hypercortisolaemia despite
the use of ketoconazole (an inhibitor of adrenal ste-
roidogenesis) the patient was started on octreotide
0.1 mg tid SC. An improvement in muscle strength
and good blood pressure control at lower doses of
anti-hypertensive medication were achieved. Dur-
ing the treatment the patient required initiation of
a replacement dose of hydrocortisone due to the
signs and symptoms of adrenal failure. Due to an
unclear chest radiogram in May 2005, following
preparation with octreotide, the patient underwent
a thoracotomy. No neuroendocrine tumour was,
however, found. Due to the persistent hypercortiso-
laemia, progressive emaciation and based on the
diagnosis of ectopic ACTH secretion, a bilateral
adrenalectomy was performed in June 2005. The
surgery proved not to be radical, as the manifesta-
tions of Cushing’s syndrome persisted. For this rea-
son, the patient was started on LAR octreotide in
June 2005 at the dose of 20 mg q4w. During oct-
reotide treatment the patient developed clinical and
biochemical signs of adrenal failure, which required
the use of hydrocortisone at replacement doses.
A considerable improvement was observed in the
patient's well-being, muscle strength and the chang-
es in body habitus (resolution of the characteristic
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adipose tissue distribution, striae and round face).
Glucose levels returned to normal and blood pres-
sure decreased. In March 2006, with a view to per-
forming somatostatin receptor scintigraphy with Oc-
treoScan, octreotide was discontinued and the re-
placement dose of hydrocortisone was maintained.
The cortisol levels determined at the subsequent
follow-up visits fell within the low normal range.
The patient has been off octreotide for the past 9
months. No clinical signs of Cushing's syndrome are
observed and laboratory tests reveal normal glu-
cose and cortisol levels. The patient still requires
replacement doses of hydrocortisone despite being
off octreotide.
Discussion
Native somatostatin and its analogues (octre-
otide, lanreotide, vapreotide) exert their biological
effects by binding with somatostatin receptors. Five
subtypes of the somatostatin receptor have so far
been identified (SSTR-1 to -5). These receptors have
been demonstrated on the surfaces of cells in pitu-
itary tumours, carcinoid tumours and pancreatic
endocrine tumours [7, 9]. Ninety percent of carcino-
id tumours and 80% of pancreatic endocrine tu-
mours express SSTR 2. Somatostatin demonstrates
equal binding affinity for all of its receptor sub-
types, while its analogues show high affinity for
SSTR 2 and SSTR 5, moderate affinity for SSTR 3 and
low or no affinity for SSTR 4 and SSTR 1 [10].
Due to its short half-life, somatostatin can exert
its therapeutic effects only if given in a continuous
intravenous infusion. Somatostatin analogues may
be given in repeated subcutaneous injections q8h.
Slow-release formulations are given intramuscular-
ly every 4 weeks (LAR octreotide) or every 2 weeks
(lanreotide PR) [9]. It is recommended to start treat-
ment with octreotide q12h to q8h and in case of
possitive effect swap to one of the long acting for-
mulation. This allows a rapid achievement of the
target serum concentration of the drug (which, in
the case of slow-release formulations, is achieved
within several months after administration) and rel-
atively rapid symptom control [2, 11]. This approach
was used in the four patients described in this pa-
per during the periods of severe signs and symp-
toms arising from excess hormone production. Re-
peated subcutaneous dosing also enables the con-
trol of adverse effects, which include gastrointesti-
nal symptoms, gall bladder dysfunction and leg
cramps. Cholelithiasis may develop during long-term
treatment with somatostatin analogues [2, 7, 11].
None of the patients presented in this paper devel-
oped the above manifestations during octreotide
treatment. Somatostatin analogue treatment is gen-
erally well tolerated and these drugs are rarely dis-
continued because of adverse effects [7].
The principal effect of somatostatin analogues
consists of the inhibition of active peptide and hor-
mone release from neuroendocrine tumour cells,
which leads to amelioration of symptoms related to
excessive hormone secretion [7, 9, 10, 12, 13]. This
effect is best documented in carcinoid syndrome.
The efficacy of lanreotide at the dose of 30 mg IM
q2w has been demonstrated by Ruszniewski et al.
[12] in a multi-centre prospective study of 39 pa-
tients with carcinoid syndrome. At six months of
treatment the incidence of flushing episodes and
loose stools reduced by half in 54% and 56% of the
patients respectively. In 42% of the patients the
24-hour urinary 5-HIAA excretion reduced by half
[12]. A high efficacy of LAR octreotide in the symp-
tomatic treatment of carcinoid syndrome has been
demonstrated by Tomassetti et al. [13]. Diarrhoea
resolved in 9 out of 10 patients and in one patient
the number of bowel movements decreased from 5
to 2 a day. Flushing episodes resolved in 9 patients;
in one patient the number of flushing episodes ini-
tially decreased but following an increase of the
dose of the drug from 20 mg to 30 mg q4w, they
resolved completely [13].
In a multi-centre European study of 55 patients
with NETs, including 48 patients with carcinoid tu-
mour, who received lanreotide at the dose of 30 mg
IM q2w, a reduction in clinical symptoms was ob-
served in 38% of the patients with carcinoid syn-
drome [14].
In the patient with carcinoid syndrome we de-
scribe in this paper octreotide also resulted in symp-
tomatic improvement and a reduction in 5-HIAA
excretion.  Despite the fact that the disease was
progressing and it was increasingly difficult to con-
trol the symptoms in the final months of the pa-
tient's life, octreotide treatment reduced the pa-
tient's suffering.
In patients with tumours secreting vasoactive
intestinal peptide (VIP) and persistent symptoms
(diarrhoea, hypokaliaemia), octreotide is the treat-
ment of choice. This especially applies to patients
with tumours that are inoperable or unresponsive
to chemotherapy [15]. Diarrhoea improves or com-
pletely resolves in 80% of patients managed with
octreotide. The clinical improvement is not always
associated with reduced serum levels of VIP, which
may suggest that octreotide may directly affect in-
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testinal function. Octreotide treatment has also been
shown potentially to modify the VIP molecule, which
results in a lower biological activity of the hormone
[10]. In the patient with typical clinical manifesta-
tions of a VIP secreting tumour we described above,
octreotide treatment reduced the number of stools,
improved the water and electrolyte balance param-
eters and ameliorated the patient's general condi-
tion. It should be emphasized that despite employ-
ing state-of-the-art diagnostic techniques the loca-
tion of the tumour could not be established. The
diagnosis was based on the characteristic clinical
manifestations, exclusion of other causes, slightly
elevated levels of chromogranin A (a neuroendo-
crine tumour marker) and the outcomes of octreotide
treatment.
The efficacy of octreotide in reducing the symp-
toms of Cushing's syndrome in the course of ectop-
ic ACTH secretion was first demonstrated in 1988
[16]. Treatment with octreotide reduces serum cor-
tisol and ACTH leading to partial or complete reso-
lution of hypercortisolaemia manifestations [17, 18].
In both patients with ectopic ACTH syndrome oct-
reotide led to the normalization of cortisol levels
and partial or complete resolution of the clinical
manifestations of Cushing's syndrome.
In addition to relieving the symptoms of exces-
sive hormone secretion by neuroendocrine tumours,
somatostatin analogues exert anti-tumour effects
that are mediated, among other factors, by sup-
pressing the secretion of growth factors, such as
insulin-like growth factor-1 (IGF-1) and epidermal
growth factor (EGF) modulating the immune sys-
tem, and by inducing apoptosis (via the SSTR-3
receptor) and inhibiting angiogenesis [10,19]. The
anti-proliferative effect of somatostatin analogues
is not as well-documented as their effects on the
endocrine function of NETs. Most studies suggest
mild to moderate effects of these drugs on tumour
regression or tumour growth suppression [10].
Arnold et al. demonstrated that octreotide exerted
an anti-proliferative effect in the form of tumour
growth suppression in patients with metastatic gas-
trointestinal NETs but was given at high doses
(200–300 mg SC tid) [20]. Aparicio et al. used stan-
dard doses of somatostatin analogues (octreotide
100 mg SC tid or lanreotide 30 mg IM q14d) and
achieved tumour growth suppression in 57% of
the patients with NETs [21].
In one of our subjects, the patient with ectopic
ACTH syndrome and a tumour of unknown nature
(type) and location, the potential anti-proliferative
effects of octreotide could be considered. During
octreotide treatment all the reversible manifesta-
tions of Cushing’s syndrome subsided and have not
reappeared, even though the drug has been discon-
tinued. The patient obviously needs further moni-
toring.
Another aspect of treatment with somatostatin
analogues is their effect on improving prognosis in
patients with NETs. A Dutch epidemiological study
of 2,391 patients with carcinoid tumour diagnosed
between 1989 and 1997 demonstrated that the
survival in patients with metastatic disease depend-
ed on the timing of diagnosis (before vs after the
year 1992, when octreotide received regulatory ap-
proval). The survival time increased from 24 to 43
months with the 3-year survival rate rising from
29% to 60%. In a multivariate analysis that took
into account the age, sex, location of the primary,
the centre providing the treatment and the timing
of the diagnosis (before vs. after the year 1992),
only the last turned out to be an independent prog-
nostic factor [22].
Although its use was interrupted, octreotide
treatment prolonged survival in the patient with
ectopic ACTH syndrome whom we describe in this
paper, as it has been proved that the 5-year survival
rate in patients with incurable hypercortisolaemia
is as great as 50% [23]. In both of our patients with
ectopic ACTH syndrome, octreotide treatment has
been an effective and survival-prolonging form of
long-term therapy that these patients could be of-
fered by contemporary medicine.
In the patient with thymic carcinoma all the
other treatment modalities, perhaps with the ex-
ception of adrenalectomy, had been attempted
(surgery, radiotherapy and chemotherapy). In the
patient with unknown location of the neuroendo-
crine tumour octreotide offers the hope that the
patient will survive until the time the site of ectop-
ic ACTH secretion can be identified. As already
mentioned, regression of the tumour resulting from
octreotide treatment cannot be ruled out in this
case.
Treatment with somatostatin analogues, espe-
cially with slow-release formulations, improves the
quality of life and patient compliance [10, 14], as
was first demonstrated in the already cited multi-
centre study of neuroendocrine tumours. Based on
the EORTC QLQ-C30 questionnaire, significant im-
provements in cognitive function, emotional state,
perception of health and sleep disorders have been
shown in patients managed with lanreotide PR [14].
Our findings in patients with NETs allow us to
believe that treatment with LAR octreotide has im-
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proved their quality of life. The partial or complete
resolution of diarrhoea in the patient with carcinoid
syndrome and the patient with manifestations of
VIPoma has offered them the possibility of normal
social functioning. Increased muscle strength and
improved well-being have allowed the patients with
ectopic ACTH syndrome to perform the activities of
daily living unaided and even to resume work. The
normalization of glycaemia has freed the patients
from the necessity to use insulin. The resolution of
the Cushingoid appearance has boosted self-esteem
and self-image in the patient with unknown loca-
tion of the NET.
Summary
Slow-release octreotide used in the treatment of
patients with neuroendocrine tumours reduces the
signs and symptoms associated with an excessive
secretion of hormones and catecholamines, improves
quality of life and, possibly, prolongs survival. This
form of treatment is the only effective method of
symptomatic relief in patients with advanced dis-
ease when surgery is either unfeasible or ineffec-
tive, and in patients with unknown location of the
neuroendocrine tumour.
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